Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIKTORY-2: Savolitinib and Durvalumab in Advanced MET Amplified Gastric Cancer
NCT05620628Phase 2Recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of savolitinib and durvalumab in gastric cancer (GC). Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2023; status: recruiting.
02
Drugs
savolitinibdurvalumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05620628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620628.